The immunotherapy field is booming, with cell therapies like chimeric antigen receptor (CAR) T cells taking the lead. According to one forecast, the market is expected to reach $6.1 billion in size by 2030 for CAR-T therapies alone. The FDA approved the world’s first CAR-T therapy, Kymriah, in 2017, and it is now available at over 130 treatment centers across the United States. [Read more…]
Brian C. Handerhan, MBA, Takes on the Newly Created Role of Vice President, Operations for Cell X Technologies, Inc.
CLEVELAND, Ohio – Cell X Technologies’ CEO Peter Johnson MD, today announced an important new hire in Brian C. Handerhan, MBA, who will take on the newly created position of Vice President, Operations. In this role, he will oversee sales, marketing, product development, and product management to drive growth in all cell therapy markets served by Cell X. [Read more…]
Professional Course on Preservation of Cellular Therapies – May 18-19, 2021
Preservation of Cellular Therapies is a professional short course founded in 2003 to provide practical training for those individuals involved in the preservation of cellular therapies. This virtual course is associated with the Biopreservation Core Resource at the University of Minnesota and will be hosted on May 18-19, 2021.
Landmark MSC Trial for Parkinson’s Disease Authorized by U.S. FDA
April 28, 2021, SUGAR LAND, Texas — Houston-area non-profit Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a Phase II double-blind placebo controlled clinical trial to assess the efficacy and safety of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells to improve activities of daily living and quality of life in subjects with Parkinson’s Disease.
The trial is the first globally to administer pure adipose-derived mesenchymal stem cells to Parkinson’s patients in such high quantities over repeat treatments. Twenty-four patients will be randomized to receive six intravenous infusions of 200 million stem cells each. [Read more…]
Horizon 2020 consortium funding to fuel cell therapy microcarrier development at denovoMATRIX
DRESDEN, Germany, April 29, 2021 — denovoMATRIX GmbH, a developer of technologies which enable high quality stem cell expansion, announced today that it will participate in the new European collaborative project funded by the European Union’s Horizon 2020 research and innovation program.
- « Previous Page
- 1
- …
- 161
- 162
- 163
- 164
- 165
- …
- 334
- Next Page »